Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members

Cell Death and Disease

Volumn 4, Issue 5, 2013, Pages

  Beaumont, T E ^a   Shekhar, T M ^a   Kaur, L ^a   Pantaki Eimany, D ^a   Kvansakul, M ^a   Hawkins, C J ^a  

^a LA TROBE UNIVERSITY   (Australia)

Author keywords

Apoptosis; Bcl 2; BH3 mimetic; Caspase; Cerevisiae; Drug development

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE; CASPASE 3; INTERLEUKIN 1BETA CONVERTING ENZYME; NAVITOCLAX; OBATOCLAX; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; TW 37; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG TARGETING; ENZYME INHIBITION; LOW DRUG DOSE; MOLECULAR MODEL; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SACCHAROMYCES CEREVISIAE; VIRUS STRAIN;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CASPASE INHIBITORS; CASPASES; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOLINES; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; SULFONAMIDES;

POXVIRIDAE; SACCHAROMYCES CEREVISIAE;

EID: 84879368693     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.143     Document Type: Article

References (60)

1. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18: 1414-1424.
2. Fischer U, Janicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003; 10: 76-100.
3. Certo M, Moore Vdel G, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
4. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008; 51: 6902-6915.
5. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
6. Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res 2010; 16: 4217-4225.
7. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
8. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16: 1030-1039.
9. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
10. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012; 3: e366.
11. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-xL and Bcl-w are not equivalent targets of ABT-737 and Navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816.
12. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
13. Whitecross KF, Alsop AE, Cluse LA, Wiegmans A, Banks KM, Coomans C et al. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009; 113: 1982-1991.
14. Wilson WH, O'Connor OA, Czuczman MS, Lacasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
15. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186.
16. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
17. Stamelos VA, Redman CW, Richardson A. Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine. J Mol Signal 2012; 7: 12.
18. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419-1421.
19. Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006; 49: 6139-6142.
20. Doshi JM, Tian D, Xing C. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer. J Med Chem 2006; 49: 7731-7739.
21. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 2007; 104: 19512-19517.
22. Buron N, Porceddu M, Brabant M, Desgue D, Racoeur C, Lassalle M et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One 2010; 5: e9924.
23. Doshi JM, Tian D, Xing C. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2- oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis. Mol Pharm 2007; 4: 919-928.
24. Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. Viral control of mitochondrial apoptosis. PLoS Pathog 2008; 4: e1000018.
25. Taylor JM, Barry M. Near death experiences: poxvirus regulation of apoptotic death. Virology 2006; 344: 139-150.
26. MacKenzie SH, Schipper JL, Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel 2010; 13: 568-576.
27. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M et al. Clinical Trial of the Pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007; 7: 218-225.
28. Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr Pharm Des 2007; 13: 367-385.
29. Celik E, Calik P. Production of recombinant proteins by yeast cells. Biotechnol Adv 2012; 30: 1108-1118.
30. Menacho-Marquez M, Murguia JR. Yeast on drugs: Saccharomyces cerevisiae as a tool for anticancer drug research. Clin Transl Oncol 2007; 9: 221-228.
31. Carmona-Gutierrez D, Eisenberg T, Buttner S, Meisinger C, Kroemer G, Madeo F. Apoptosis in yeast: triggers, pathways, subroutines. Cell Death Differ 2010; 17: 763-773.
32. Vachova L, Palkova Z. Caspases in yeast apoptosis-like death: facts and artefacts. FEMS Yeast Res 2007; 7: 12-21.
33. Sato T, Hanada M, Bodrug S, Irie SJ, Iwama N, Boise LH et al. Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 1994; 91: 9238-9242.
34. Puryer MA, Hawkins CJ. Human, insect and nematode caspases kill Saccharomyces cerevisiae independently of YCA1 and Aif1p. Apoptosis 2006; 11: 509-517.
35. Jabbour AM, Puryer MA, Yu JY, Lithgow T, Riffkin CD, Ashley DM et al. Human Bcl-2 cannot directly inhibit the Caenorhabditis elegans Apaf-1 homologue CED-4, but can interact with EGL-1. J Cell Sci 2006; 119: 2572-2582.
36. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD et al. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 2008; 105: 18081-18087.
37. Manon S, Chaudhuri B, Guerin M. Release of cytochrome c and decrease of cytochrome c oxidase in Bax-expressing yeast cells, and prevention of these effects by coexpression of Bcl-xL. FEBS Lett 1997; 415: 29-32.
38. Juhasova B, Bhatia-Kissova I, Polcicova K, Mentel M, Forte M, Polcic P. Reconstitution of interactions of Murine gammaherpesvirus 68 M11 with Bcl-2 family proteins in yeast. Biochem Biophys Res Commun 2011; 407: 783-787.
39. Juhasova B, Mentel M, Bhatia-Kissova I, Zeman I, Kolarov J, Forte M et al. BH3-only protein Bim inhibits activity of antiapoptotic members of Bcl-2 family when expressed in yeast. FEBS Lett 2011; 585: 2709-2713.
40. Hawkins CJ, Wang SL, Hay BA. A cloning method to identify caspases and their regulators in yeast: identification of Drosophila IAP1 as an inhibitor of the Drosophila caspase DCP-1. Proc Natl Acad Sci USA 1999; 96: 2885-2890.
41. Wang SL, Hawkins CJ, Yoo SJ, Muller HA, Hay BA. The Drosophila caspase inhibitor DIAP1 is essential for cell survival and is negatively regulated by REAPER, HID and GRIM, which disrupt DIAP1-caspase interactions. Cell 1999; 98: 453-463.
42. Hawkins CJ, Wang SL, Hay BA. Monitoring activity of caspases and their regulators in yeast Saccharomyces cerevisiae. Methods Enzymol 2000; 322: 162-174.
43. Hawkins CJ, Yoo SJ, Petersen EP, Wang SL, Vernooy SY, Hay BA. The Drosophila caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM. J. Biol. Chem 2000; 275: 27084-27093.
44. Hawkins CJ, Silke J, Verhagen AM, Foster R, Ekert PG, Ashley DM. Analysis of candidate antagonists of IAP-mediated caspase inhibition using yeast reconstituted with the mammalian Apaf-1-activated apoptosis mechanism. Apoptosis 2001; 6: 331-338.
45. Jabbour AM, Ekert PG, Coulson EJ, Knight MJ, Ashley DM, Hawkins CJ. The p35 relative, p49, inhibits mammalian and Drosophila caspases including DRONC and protects against apoptosis. Cell Death Differ 2002; 9: 1311-1320.
46. Ho PK, Jabbour AM, Ekert PG, Hawkins CJ. Caspase-2 is resistant to inhibition by inhibitor of apoptosis proteins (IAPs) and can activate caspase-7. FEBS J 2005; 272: 1401-1414.
47. Brand IL, Green MM, Civciristov S, Pantaki-Eimany D, George C, Gort TR et al. Functional and biochemical characterization of the baculovirus caspase inhibitor MaviP35. Cell Death Dis 2011; 2: e242.
48. Kolaczkowski M, Kolaczowska A, Luczynski J, Witek S, Goffeau A. In vivo characterization of the drug resistance profile of the major ABC transporters and other components of the yeast pleiotropic drug resistance network. Microb Drug Resist 1998; 4: 143-158.
49. Zhang M, Hanna M, Li J, Butcher S, Dai H, Xiao W. Creation of a hyperpermeable yeast strain to genotoxic agents through combined inactivation of PDR and CWP genes. Toxicol Sci 2010; 113: 401-411.
50. Hwang JJ, Kuruvilla J, Mendelson D, Pishvaian MJ, Deeken JF, Siu LL et al. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 2010; 16: 4038-4045.
51. Okamoto T, Campbell S, Mehta N, Thibault J, Colman PM, Barry M et al. Sheeppox virus SPPV14 encodes a Bcl-2-like cell death inhibitor that counters a distinct set of mammalian pro-apoptotic proteins. J Virol 2012; 86: 11501-11511.
52. Banadyga L, Lam SC, Okamoto T, Kvansakul M, Huang DC, Barry M. Deerpox virus encodes an inhibitor of apoptosis that regulates Bak and Bax. J Virol 2011; 85: 1922-1934.
53. Hsu YT, Youle RJ. Nonionic detergents induce dimerization among members of the bcl-2 family. J Biol Chem 1997; 272: 13829-13834.
54. Mischak R. Apoptosis. ICN/ESP Caspase inhibitors: Applications in vivo and in vitro. ICN Bioconcepts 2002; 8: 1-5.
55. Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodriguez-Carmona E, Baumann K et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact 2008; 7: 11.
56. Hinds MG, Lackmann M, Skea GL, Harrison PJ, Huang DC, Day CL. The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO J 2003; 22: 1497-1507.
57. Wilson-Annan J, O'Reilly LA, Crawford SA, Hausmann G, Beaumont JG, Parma LP et al. Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J Cell Biol 2003; 162: 877-887.
58. White E, Sabbatini P, Debbas M, Wold WS, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor alpha. Mol Cell Biol 1992; 12: 2570-2580.
59. Jungwirth H, Kuchler K, Yeast ABC. transporters-a tale of sex, stress, drugs and aging. FEBS Lett 2006; 580: 1131-1138.
60. DeGorter MK, Xia CQ, Yang JJ, Kim RB. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol 2012; 52: 249-273.